Hisamitsu Pharmaceutical
The Hisamitsu Pharmaceutical Co., Inc., headquartered in Tosu and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialised in transdermal drug delivery system technology since the introduction of its original line of patches in 1903.
Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration.
History
Hisamitsu Pharmaceutical was founded in 1847 under the name Komatsuya. It was established in Tosu, which is now in Saga Prefecture, on the island of Kyushu. This region is well known in Japan for its tradition of herbal medicines.The prototype of Hisamitsu's Salonpas patch was created in 1903 through the application of asahi mankinko, a poultice consisting of rubbing ointment pasted onto Japanese paper. The product line developed from this traditional remedy was introduced in 1934 and first exported to overseas markets in 1937.
A subsidiary branch was opened in Taiwan in 1960. In 1975 a joint company was established in Indonesia. More subsidiaries followed in Brazil in 1986, in Singapore and in the United States in 1987. Hisamitsu Vietnam Pharmaceutical Co., Ltd. was established in Vietnam in 1994. In 1998 Hisamitsu U.K. opened in London and a research laboratory was established in California.
In 1965 the company changed its name to Hisamitsu Pharmaceutical Co., Ltd., and in 1972 it was listed on the first section of the Tokyo Stock Exchange. The company began manufacturing and marketing prescription drugs during the 1970s. In 1988, it launched Mohrus, and in 1995, Mohrus-Tape, both prescription external anti-inflammatory drugs. Salonpas Pain Relief Patch and Salonpas Arthritis Pain were approved for over the counter sales in the United States in 2008. In 2009, Hisamitsu acquired Noven Pharmaceuticals, a specialty prescription drug transdermal pharmaceutical company based in Florida.
Locations
Hisamitsu operates two primary bases in Japan, in Saga Prefecture and in Tokyo. It has two subsidiaries in the United States: Hisamitsu America, Inc. in Florham Park, NJ, and Noven Pharmaceuticals in Miami, FL. It has a clinical research department in New Jersey and a research laboratory in Carlsbad, CA. Hisamitsu also has overseas facilities in Britain, Australia, Brazil, the Philippines, Hong Kong, Singapore, Vietnam, Indonesia, Taiwan and Malaysia.Hisamitsu America is the sole importer and distributor of Salonpas products for the United States and Canada. It was founded in 1987.